62
Participants
Start Date
October 31, 2002
Primary Completion Date
March 31, 2003
Study Completion Date
March 31, 2003
Levalbuterol HFA MDI
"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
Racemic Albuterol
"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
Los Angeles
Signal Hill
Denver
Minneapolis
Burke
Sumitomo Pharma America, Inc.
INDUSTRY